See more : Nyxio Technologies Corporation (NYXO) Income Statement Analysis – Financial Results
Complete financial analysis of Ibere Pharmaceuticals (IBER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ibere Pharmaceuticals, a leading company in the Shell Companies industry within the Financial Services sector.
- China Wafer Level CSP Co., Ltd. (603005.SS) Income Statement Analysis – Financial Results
- 450 Plc (450.L) Income Statement Analysis – Financial Results
- CLC Industries Limited (SPENTEX.BO) Income Statement Analysis – Financial Results
- Morguard Real Estate Investment Trust (MGRUF) Income Statement Analysis – Financial Results
- JAS Asset Public Company Limited (J.BK) Income Statement Analysis – Financial Results
Ibere Pharmaceuticals (IBER)
About Ibere Pharmaceuticals
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
| Metric | 2021 |
|---|---|
| Revenue | 0.00 |
| Cost of Revenue | 1.00M |
| Gross Profit | -1.00M |
| Gross Profit Ratio | 0.00% |
| Research & Development | 0.00 |
| General & Administrative | 0.00 |
| Selling & Marketing | 0.00 |
| SG&A | 0.00 |
| Other Expenses | 1.00M |
| Operating Expenses | 1.00M |
| Cost & Expenses | 1.00M |
| Interest Income | 17.12K |
| Interest Expense | 0.00 |
| Depreciation & Amortization | -2.55M |
| EBITDA | -3.55M |
| EBITDA Ratio | 0.00% |
| Operating Income | -1.00M |
| Operating Income Ratio | 0.00% |
| Total Other Income/Expenses | 2.57M |
| Income Before Tax | 1.56M |
| Income Before Tax Ratio | 0.00% |
| Income Tax Expense | -17.12K |
| Net Income | 1.56M |
| Net Income Ratio | 0.00% |
| EPS | 0.34 |
| EPS Diluted | 0.34 |
| Weighted Avg Shares Out | 14.87M |
| Weighted Avg Shares Out (Dil) | 14.87M |
IberAmerican Responds to Recent Promotional Activity Pursuant to OTC Markets' Request
Cboe Canada Continues to Fuel the Innovation Economy With Public Launch of IberAmerican Lithium
Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report
Source: https://incomestatements.info
Category: Stock Reports